The AIM-listed company said in his new role, Ullmann will be responsible for overseeing clinical development of MaxCyte’s CARMA drug development program, with the company’s first candidate, MCY-M11, is expected to enter the clinic this year.
The global cell-based medicines and life sciences company said Ullmann brings more than 25 years of experience in clinical oncology and drug development.
He was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where he oversaw all clinical development and operations, shaped corporate strategy and was directly involved in business development activities.
He also worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) and held research roles at the National Institute of Health.
Doug Doerfler, MaxCyte’s CEO, said: “His broad experience in cancer therapy drug development will be invaluable at this stage in MaxCyte’s evolution form a cell engineering technology company to a drug developer with a pipeline of CARMA drug candidate programs.”
The CEO added: “Furthermore, with his deep understanding of the development of immune-oncology therapies and other cancer treatments, Claudio will help us to advance our Flow Electroporation technology to enable our partners to make important medical.